Thibault Honegger

Researcher's interest in a few words:

Main field of activity

technology development;
biologic model development.

Target organs

brain;
liver;
kidney;
muscle;
skin;
blood;
eye;
gut (microbiota).

Main collaborations

NETRI focus on building partnerships that go beyond commercial alliances and provide combined breakthrough solutions and aim at maintaining the interoperability and multi-compatibility of our devices.

Technology providers (Axion Biosystems, that has resulted in NeuroFluidics™ MEA line creation that integrate MEA for recording the neurons electrical activity);

Biology providers (Axol Bioscience, that has resulted in organs-on-chip kits creation including our microfluidic devices and Axol’ cells & reagents);
CRO & Biotech ( Etap-Lab, that has resulted in BIO-DIAMOND project creation (AD, PD & ALS model development), winner of the « Innovation in Biotherapy and Bioproduction », funded by the French government as part of the Plan France 2030).

Keywords

Type/models systems

Organoids, organ-on-a-chip.

Physio-pathological models

Cancer, neurodegenerative disease, infectious disease, inflammatory disease, immune disorders, skin disease, hematological disease, rare-orphan disease.

Application areas

Organ development and physiopathology studies, diseases models, organ interaction studies, drug discovery, clinical drug efficacy, medical treatments, physiological responses, toxicity, drug safety, toxicology testing, ADME (absorption, distribution, metabolism, excretion), DMPK (Drug Metabolism and PharmacoKinetics), personalized medecine.

Technologies

microfluidic chips & biosensors;
chip production, scale-up manufacturability, miniaturization & standardization;
cell biology, cell production, stem cells, iPSC & cell media;
readout technologies, optical readers, fluoreaders, imaging & computational analysis.

Main research or activities topics

NETRI, an industrial start-up, offers the healthcare industry (pharmaceutical, dermo-cosmetics & nutritional health companies) the possibility of generating mini human organs on chip which, coupled with AI treatments, can predict the clinical effect of a drug candidate. NETRI offers its customers support throughout the development of their drug/product candidate, providing predictive answers on toxicity, efficacy and modes of action.
NETRI is developing organs-on-chip technologies that enable different organs to be innervated, vascularized and interconnected using human stem cells.

The natural innervations of all organs make it possible to use the electrical signals of neurons as a natural biosensor of a biological effect, enabling a digital signature to be extracted for each therapeutic compound tested. These signatures, obtained from clinical studies of users’ drug candidates or molecules, are used to train NETRI’s AI algorithm and build digital libraries for each therapeutic indication. NETRI’s solutions can thus predict the clinical toxicological and efficacy responses of drug candidates by comparing their signatures with digital libraries.

NETRI